| Mutagencity Testing of WR238605 Succinate |
03 May 1996 |
115 pages |
| Authors:
Barry S Levine; Patrick T Curry; Richard H San; ILLINOIS UNIV AT CHICAGO CIRCLE DEPT OF PHARMACOLOGY
|
 | WR238605 Succinate was tested for point mutations and chromosomal aberrations in three in vitro mutagenicity tests. WR238605 Succinate was shown to be negative in the chromosomal aberrations test but was equivocal in the mouse lymphoma assay, which tested for point mutations. Accordingly, a second in vitro test for point mutations, the CHO/HGPRT assay, was performed. WR238605 Succinate was negative in this follow-up point mutation assay, and a subsequent confirmatory in ... |
|
| In Vitro Mutagenicity Testing of WR242511 Tartrate |
07 Aug 1994 |
104 pages |
| Authors:
Barry S Levine; Donald L Putman; C A Bigger; Richard H San; ILLINOIS UNIV AT CHICAGO CIRCLE DEPT OF PHARMACOLOGY
|
| WR242511 Tartrate was tested for in vitro mutagenic potential. The Ames Test and the Mouse Lymphoma Assay were utilized to assess potential point mutations, whereas the ability to induce chromosome aberrations was tested in Chinese Hamster Ovary cells. WR242511 Tartrate was negative in the three assays utilized. |
|
| Four Week Oral Dose Range-Finding Study of WR242511 in Dogs |
09 Mar 1994 |
114 pages |
| Authors:
Barry S Levine; Clyde W Wheeler; ILLINOIS UNIV AT CHICAGO CIRCLE DEPT OF PHARMACOLOGY
|
| This study evaluated the toxicity of WR242511 tartrate in dogs following four weeks of daily administration by gelatin capsule. The primary toxic effects of WR242511 tartrate were seen in the RBCs, liver and the lung. Anemia and methemoglobinemia were observed in all the dose levels tested. Compensatory changes to the anemic state included macrocytosis, reticulocytosis and increased nucleated RBCs. Decreases in body weight and food consumption were seen at the ... |
|
| Preclinical Toxicology Studies For New Drugs and Vaccines |
07 DEC 92 |
|
| Authors:
Barry S. Levine; ILLINOIS UNIV AT CHICAGO CIRCLE DEPT OF PHARMACOLOGY
|
 | The purpose of this study is to determine specific target organ toxicity, dose-response relationships, and a no adverse effect level of WR6026 in Beagle dogs following thirteen weeks of daily oral administration. In addition, the reversibility of these toxic effects over a 90-day recovery period will be assessed. Treatment was initiated on 5/7/92. Necropsies were conducted on 8/6-7/92 and 11/5-6/92 after the three month treatment period and a three month ... |
|
Reports by Corporate Author
